GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
F

Feng Chi Biotech 6744.TWO · TWD

Health Care · Taipei Exchange · 🇹🇼 Taiwan

Compare

12.50

+2.04%

Close of 9 Nov 2026, in TWD

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

About Feng Chi Biotech

Its shares trade on Taipei Exchange under the ticker 6744.TWO. It has been listed since 25 September 2019. In the fiscal year to 31 December 2025, it reported revenue of TWD 177.4m and net income of TWD 14.5m. At that date it held total assets of TWD 287.9m and shareholders' equity of TWD 239.9m.

Feng Chi Biotech Corp. provides prenatal testing, new born screening, life science and microbiological testing services. The company is headquartered in Taipei City, Taipei. The company went IPO on 2019-09-25. The Company’s products include prenatal and neonatal testing reagents and instruments, genetic testing analysis and development services, research instruments and reagents, industrial microbiology and food testing reagents, and among others. The firm's products are mainly sold to Taiwan, China mainland, Japan, South Korea, Southeast Asia and India, as well as other overseas regions.

Figures and description from our data supplier, not checked against the company's own report.

Company facts

Sector
Health Care
Industry
Health Care Providers & Services
Listed since
25 Sept 2019

Leadership

Pay as last reported

  • Mr. Hongming ZhangChairman of the Board, General Manager, since 2000
  • Ms. Meizhen LuChief Financial Officer, Director, since 2004
  • Ms. Peiyi LinDeputy General Manager-Sales Division
  • Mr. Yaoren ZhangChief Research & Development Officer
  • Jisheng DaiDirector
  • Mr. Min ZhangDirector
  • Mr. Bonian ChenIndependent Director
  • Mr. Jianlong HongIndependent Director
  • Mr. Zhu LiuIndependent Director

Environmental, social and governance

Scores out of 100, from our data supplier

ESG
Overall
0
Environment
0
Social
0
Governance
0

SWOT analysis

AI-generated by our data supplier. Not written or checked by our editors.

AI-generated

Strengths

  • Prenatal and neonatal testing reagents are sold in Taiwan and China mainland.
  • Genetic testing analysis services cover Japan and South Korea markets.
  • Industrial microbiology reagents target Southeast Asia and India regions.

Weaknesses

  • Limited product range in the Financials sector for Taiwan market.
  • No presence in the Real Estate industry within Southeast Asia.
  • Insufficient focus on Information Technology services in South Korea.

Opportunities

  • Expanding genetic testing services to India's growing healthcare market.
  • Increasing demand for microbiology reagents in Southeast Asia's food industry.
  • Growing need for life science testing in China mainland's urban centers.

Threats

  • Competition from local firms in Taiwan's Health Care sector.
  • Regulatory changes affecting prenatal testing in China mainland.
  • Economic downturns impacting South Korea's healthcare spending.

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.